CRBP Corbus Pharmaceuticals Holdings, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

CRBP [NASD]

Corbus Pharmaceuticals Holdings, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.68	Insider Own	4.93%	Shs Outstand	73.89M	Perf Week	-12.54%
Market Cap	80.04M	Forward P/E	-	EPS next Y	-1.04	Insider Trans	0.00%	Shs Float	73.07M	Perf Month	-43.05%
Income	-115.10M	PEG	-	EPS next Q	-0.42	Inst Own	75.80%	Short Float	47.52%	Perf Quarter	-85.36%
Sales	7.20M	P/S	11.12	EPS this Y	-14.50%	Inst Trans	29.21%	Short Ratio	7.26	Perf Half Y	-83.45%
Book/sh	0.66	P/B	1.48	EPS next Y	38.10%	ROA	-164.10%	Target Price	-	Perf Year	-81.23%
Cash/sh	0.78	P/C	1.26	EPS next 5Y	-	ROE	-430.80%	52W Range	1.02 - 9.78	Perf YTD	-82.06%
Dividend	-	P/FCF	-	EPS past 5Y	-61.90%	ROI	-	52W High	-89.98%	Beta	1.81
Dividend %	-	Quick Ratio	2.10	Sales past 5Y	-	Gross Margin	-	52W Low	-3.96%	ATR	0.16
Employees	141	Current Ratio	2.10	Sales Q/Q	-99.00%	Oper. Margin	-	RSI (14)	22.55	Volatility	6.72% 10.76%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-	Profit Margin	-	Rel Volume	1.22	Prev Close	1.02
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 06 BMO	Payout	-	Avg Volume	4.78M	Price	0.98
Recom	2.70	SMA20	-31.65%	SMA50	-76.80%	SMA200	-83.20%	Volume	5,814,093	Change	-3.96%

Sep-08-20

Downgrade

ROTH Capital

Buy → Neutral

$40 → $3

Sep-08-20

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

Sep-08-20

Downgrade

Jefferies

Buy → Hold

$18 → $2.50

Sep-08-20

Downgrade

BTIG Research

Buy → Neutral

Jul-07-20

Initiated

ROTH Capital

Buy

$40

Jun-17-20

Initiated

BTIG Research

Buy

$22

Mar-26-20

Initiated

Nomura

Buy

$12

Apr-05-19

Initiated

Jefferies

Buy

Mar-20-19

Initiated

Oppenheimer

Outperform

$28

Jan-11-19

Reiterated

Cantor Fitzgerald

Overweight

$36 → $38

Dec-26-18

Initiated

H.C. Wainwright

Buy

$24

Dec-07-18

Initiated

RBC Capital Mkts

Outperform

$23

Oct-24-18

Initiated

B. Riley FBR

Buy

$22

Jan-19-18

Initiated

Raymond James

Outperform

$24

Dec-14-17

Reiterated

Cantor Fitzgerald

Overweight

$24 → $28

Nov-08-17

Reiterated

Noble Financial

Buy

$16 → $20

Sep-29-17

Resumed

Noble Financial

Buy

$16

Mar-30-17

Reiterated

Cantor Fitzgerald

Overweight

$17 → $24

Nov-15-16

Reiterated

JMP Securities

Mkt Outperform

$9 → $20

Nov-11-16

Reiterated

Noble Financial

Buy

$19

Oct-08-20 08:05AM	Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates GlobeNewswire
Oct-07-20 10:46AM	Corbus Stock Down as Lenabasum Fails to Meet Primary Endpoint Zacks
Oct-06-20 07:05AM	Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint GlobeNewswire -35.98%
Oct-04-20 09:46AM	How Much Of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Do Institutions Own? Simply Wall St.
Sep-25-20 08:53AM	Are Options Traders Betting on a Big Move in Corbus (CRBP) Stock? Zacks
Sep-24-20 09:54AM	Understanding Corbus Pharmaceuticals's Unusual Options Activity Benzinga
Sep-10-20 10:01AM	Understanding Corbus Pharmaceuticals's Unusual Options Activity Benzinga -6.97%
Sep-08-20 10:00AM	Why Corbus Pharmaceuticals Is Getting Slammed Today Motley Fool -75.89%
07:05AM	Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis GlobeNewswire
Sep-04-20 09:40AM	Understanding Corbus Pharmaceuticals's Unusual Options Activity Benzinga
Aug-25-20 09:19AM	Implied Volatility Surging for Corbus Pharmaceuticals (CRBP) Stock Options Zacks
Aug-24-20 06:30AM	2 Dirt-Cheap Robinhood Stocks That Could Skyrocket Motley Fool
Aug-20-20 10:17AM	Are Insiders Buying Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock? Simply Wall St. +5.45%
Aug-16-20 08:15AM	3 Stocks Robinhood Investors Love Motley Fool
Aug-14-20 10:31AM	Looking Into Corbus Pharmaceuticals's Return On Capital Employed Benzinga
Aug-06-20 07:05AM	Corbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates GlobeNewswire -11.47%
Aug-05-20 09:25AM	Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis GlobeNewswire
Aug-03-20 08:05AM	Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences GlobeNewswire +8.29%
Jul-30-20 08:05AM	Corbus Pharmaceuticals to Report Second Quarter Results on August 6, 2020 GlobeNewswire
Jul-29-20 08:05AM	Corbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital GlobeNewswire -6.26%
Jul-21-20 10:02AM	Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock? Zacks
Jul-17-20 04:21PM	Better Buy: GW Pharmaceuticals vs. Corbus Pharmaceuticals Motley Fool
Jul-15-20 02:38PM	What Does Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) CEO Pay Reveal? Simply Wall St.
Jul-08-20 08:05AM	Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors GlobeNewswire
Jul-05-20 09:58PM	Corbus Pharmaceuticals Holdings Inc (CRBP): Are Hedge Funds Right About This Stock? Insider Monkey
Jun-29-20 08:05AM	Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress GlobeNewswire
Jun-22-20 08:05AM	Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis GlobeNewswire
Jun-18-20 10:56AM	2 Strong Buy Small-Cap Stocks That Could See Outsized Gains TipRanks
08:51AM	Is the Options Market Predicting a Spike in Corbus Pharmaceuticals (CRBP) Stock? Zacks
Jun-01-20 09:00AM	Is Corbus Pharmaceuticals (CRBP) Stock a Solid Choice Right Now? Zacks
08:05AM	Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis GlobeNewswire
May-28-20 06:53AM	Will Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Spend Its Cash Wisely? Simply Wall St.
May-27-20 08:05AM	Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis GlobeNewswire
May-22-20 08:05AM	Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress GlobeNewswire +5.22%
May-18-20 03:09AM	Edited Transcript of CRBP earnings conference call or presentation 11-May-20 12:30pm GMT Thomson Reuters StreetEvents
May-15-20 12:00PM	Corbus Pharmaceuticals (CRBP) Moves to Buy: Rationale Behind the Upgrade Zacks +5.53%
08:05AM	Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences GlobeNewswire
May-14-20 09:30AM	Do Options Traders Know Something About Corbus Pharmaceuticals (CRBP) Stock We Don't? Zacks
May-11-20 09:55AM	Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:05AM	Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates GlobeNewswire
May-04-20 08:05AM	Corbus Pharmaceuticals to Report First Quarter Results on May 11, 2020 GlobeNewswire +7.97%
Apr-30-20 04:15PM	Viela Bio Announces Election of Rachelle Jacques to its Board of Directors GlobeNewswire
Apr-29-20 08:05AM	Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & Rheumatology GlobeNewswire
Apr-28-20 07:05AM	Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Shareholders Booked A 86% Gain In The Last Five Years Simply Wall St.
Apr-02-20 08:58AM	Implied Volatility Surging for Corbus (CRBP) Stock Options Zacks
04:00AM	Edited Transcript of CRBP earnings conference call or presentation 12-Mar-20 12:30pm GMT Thomson Reuters StreetEvents
Mar-14-20 08:52AM	Corbus Pharmaceuticals Holdings, Inc. Just Reported Earnings, And Analysts Cut Their Target Price Simply Wall St.
Mar-12-20 08:55AM	Corbus Pharmaceuticals (CRBP) Reports Q4 Loss, Lags Revenue Estimates Zacks -7.52%
07:05AM	Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results GlobeNewswire
06:30AM	Corbus Pharmaceuticals Holdings, Inc. to Host Earnings Call ACCESSWIRE
Mar-10-20 08:05AM	Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director GlobeNewswire +8.59%
07:14AM	Did Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Insiders Buy Up More Shares? Simply Wall St.
Mar-05-20 08:05AM	Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020 GlobeNewswire -5.87%
Mar-03-20 12:30PM	Earnings Preview: Corbus Pharmaceuticals (CRBP) Q4 Earnings Expected to Decline Zacks
Feb-11-20 04:01PM	Corbus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares GlobeNewswire
Feb-10-20 08:58AM	Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock? Zacks
Feb-07-20 09:02AM	Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire -7.87%
Feb-06-20 04:01PM	Corbus Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-31-20 03:45PM	Top Marijuana Stocks on the NASDAQ Investopedia
Jan-25-20 08:09AM	Is Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) A Volatile Stock? Simply Wall St.
Dec-19-19 08:07AM	Does Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Pay Matter? Simply Wall St.
Dec-17-19 04:07PM	Hedge Funds Are Selling Corbus Pharmaceuticals Holdings Inc (CRBP) Insider Monkey
Dec-09-19 08:05AM	Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System GlobeNewswire
Nov-18-19 08:17AM	Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis GlobeNewswire
Nov-16-19 09:40PM	Edited Transcript of CRBP earnings conference call or presentation 7-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-12-19 08:05AM	Corbus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference in London GlobeNewswire
07:20AM	We Think Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Can Afford To Drive Business Growth Simply Wall St.
Nov-11-19 08:05AM	Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting GlobeNewswire
Nov-07-19 11:15AM	Corbus Pharmaceuticals (CRBP) Reports Q3 Loss, Tops Revenue Estimates Zacks -7.96%
07:05AM	Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates GlobeNewswire
Nov-05-19 01:00PM	3 Under-the-Radar Stocks Top Insiders Are Snapping Up TipRanks
Nov-04-19 08:05AM	Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2019 Operational and Financial Results on November 7, 2019 GlobeNewswire
Nov-01-19 12:08PM	Were Hedge Funds Right About Selling Corbus Pharmaceuticals (CRBP)? Insider Monkey
Oct-13-19 10:06AM	What Percentage Of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Do Insiders Own? Simply Wall St.
Oct-03-19 08:05AM	Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2019 ACR Annual Meeting GlobeNewswire
Oct-01-19 09:03AM	Marijuana stocks are oversold heres how to know when to buy them MarketWatch
Sep-13-19 07:21AM	Health Check: How Prudently Does Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Use Debt? Simply Wall St.
Aug-16-19 12:00AM	Edited Transcript of CRBP earnings conference call or presentation 8-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-14-19 08:32AM	Have Insiders Been Buying Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares This Year? Simply Wall St. -6.07%
01:35AM	Corbus Pharmaceuticals Holdings, Inc. (CRBP) Q2 2019 Earnings Call Transcript Motley Fool
Aug-12-19 12:15PM	Corbus Pharmaceuticals Holdings Inc (CRBP) COO Robert Paul Discordia Bought $87,900 of Shares GuruFocus.com
Aug-08-19 03:00PM	What You'll Want to Know About Corbus Pharmaceuticals' Q2 Results Motley Fool
11:15AM	Corbus Pharmaceuticals (CRBP) Q2 Earnings and Revenues Beat Estimates Zacks
07:05AM	Corbus Pharmaceuticals Reports 2019 Second Quarter Financial Results and Provides Clinical and Corporate Updates GlobeNewswire
Jul-12-19 01:32PM	How Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Can Impact Your Portfolio Volatility Simply Wall St.
Jul-10-19 05:51PM	Kadmon Initiates Dosing in Study for Systemic Sclerosis Drug Zacks
Jul-03-19 05:00PM	Horizons ETFs Rebalances Marijuana-Focused ETFs CNW Group
Jun-26-19 02:12PM	Money flows in 17 popular marijuana stocks show fewer short squeezes MarketWatch
Jun-17-19 08:05AM	Corbus Pharmaceuticals to Host 2019 R&D Day in New York City GlobeNewswire
Jun-13-19 07:04PM	Understanding Medical Cannabis vs. Recreational Cannabis Stocks Investopedia
Jun-12-19 08:05AM	Lenabasum Open-Label Extension Data to be Presented at EULAR 2019 Continue to Show a Favorable Safety Profile and Improvement in Efficacy Outcomes in Systemic Sclerosis and Dermatomyositis Phase 2 Studies GlobeNewswire
Jun-10-19 11:42PM	Edited Transcript of CRBP earnings conference call or presentation 9-May-19 12:30pm GMT Thomson Reuters StreetEvents
06:39PM	Robbins Arroyo LLP: Corbus Pharmaceuticals Holdings, Inc. (CRBP) Sued for Misleading Shareholders Business Wire
May-29-19 08:05AM	Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in June GlobeNewswire
May-28-19 08:05AM	Corbus Pharmaceuticals Announces Presentation of Six Abstracts at EULAR 2019 Annual Meeting GlobeNewswire
May-24-19 09:16AM	Does Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Pay Compare Well With Peers? Simply Wall St.
May-23-19 08:17AM	Is Corbus Pharmaceuticals a Buy Now? Motley Fool
May-15-19 08:05AM	Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in May GlobeNewswire
May-13-19 04:25PM	SHAREHOLDER ALERT: CRBP FSNN MWA AAPL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire -5.46%
03:00PM	CRBP, NIO & CORT Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Class Action GlobeNewswire

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Millian Craig Stuart	Chief Commercial Officer	Mar 17	Buy	4.25	2,000	8,500	12,000	Mar 18 01:18 PM
Cohen Yuval	Chief Executive Officer	Mar 17	Buy	3.49	4,300	15,007	71,090	Mar 17 01:14 PM
Discordia Robert Paul	Chief Operating Officer	Mar 17	Buy	3.54	2,840	10,054	35,490	Mar 18 11:21 AM
White Barbara	Chief Medical Officer	Mar 17	Buy	3.63	15,606	56,650	206,217	Mar 18 10:37 AM
White Barbara	Chief Medical Officer	Nov 12	Buy	4.38	3,424	14,992	190,611	Nov 13 10:00 AM
Cohen Yuval	Chief Executive Officer	Nov 12	Buy	4.26	1,430	6,092	66,790	Nov 12 01:02 PM
Millian Craig Stuart	Chief Commercial Officer	Nov 11	Buy	4.38	1,000	4,380	10,000	Nov 12 11:07 AM
Discordia Robert Paul	Chief Operating Officer	Nov 11	Buy	4.62	2,500	11,559	32,650	Nov 12 09:57 AM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience